30 closest matches · ranked by relevance
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
Metabolic Acidosis
Primary: Subjects With Change From Baseline in Serum Bicarbonate of ≥ 4 mEq/L or Serum Bicarbonate Within the Normal Range — 59.2; 22.5; 55.8; 21.3 percentage of participants…
Chronic Kidney Disease · Metabolic Acidosis
Primary: Sit to Stand to Sit Speed: Time Taken to Sit to Stand to Sit 10 Times — 23.8; 22.9 seconds
Cardiac Arrest · Metabolic Acidosis
Primary: Return of Spontaneous Circulation (ROSC) — 4; 16 ROSC percents of each group
Acidosis
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE — 14; 13; 9; 17 Participants
End Stage Renal Disease
Primary: Peridialytic Arterialized Blood Bicarbonate Concentrations — 25.7; 27.1; 27.2; 27.4 mEq/l — p=<0.0001
Chronic Kidney Disease · Disability
Primary: Blood Bicarbonate — 22.8; 23.2 mmol/L
Metabolic Acidosis · Chronic Kidney Disease · Cognitive Dysfunction
Primary: Change in Cognitive Function Composite Score at 12 Months — 52.3; 47.3; 53.5; 49.3 T-score
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
Epilepsy
Primary: Salivary Lactic Acid Levels With Seizures — 8.16 mmol/L
Chronic Kidney Disease · Metabolic Acidosis
Primary: Change in Brachial Artery Flow Mediated Dilation — 3.99; 3.78; 4.25; 4.43 percentage
Chronic Kidney Disease · Cardiovascular Disease · Metabolic Syndrome
Primary: Change is Leptin to Adiponectin Ratio (LAR) — 2.2; 1.3; 1.3; 1.4 ng/micrograms
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Chronic Renal Insufficiency · Diabetes Mellitus
Primary: Change in Urinary Transforming Growth Factor Beta 1 (TGF-b1) — 7.6; -4.4 percent change
Anesthesia
Primary: Change in Base Deficit — -1.5; -1.2; -0.5 mEq/L
Septic Shock
Primary: Lactate Level 24 Hours After the First Study Medication Dose — 2.6; 2.5 mmol/L — p=0.40
Osteoporosis · Sarcopenia
Primary: Biochemical Markers of Bone Turnover — -6.25; -3.36; -0.14; 0.5 nmol/mmol
Hypertension
Primary: Change in Fasting Plasma Glucose From Week 4 to Week 16 — -5.6; 2.3 mg/dL
Heart Failure · Type 2 Diabetes Mellitus
Primary: Cardiac Output (CO) — 5.02; 4.54; 5.93; 5.10 mL/min
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
Kidney Failure, Acute · Renal Replacement Therapy
Primary: Number of Participants Who Developed Acute Kidney Injury Within 72 Hours — 17; 14 Participants
Diabetes Mellitus · Lactic Acidosis
Primary: Incidence of Lactic Acidosis — 0; 0 participants
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Primary: Number of Participants With Adverse Events (AEs), Serious AEs, and AEs Leading to Study Discontinuation — 13; 6; 8; 21 Participants
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
Type 1 Diabetes · Diabetic Nephropathy · Diabetic Kidney Disease
Primary: Change in Urine Uric Acid Concentration (Increased Solubility) by Assay — 23.81; 22.30 mg/dl
Bone Diseases, Metabolic · Osteoporosis, Postmenopausal
Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine
Diabetes Mellitus, Type 2
Primary: First-Phase Insulin Release (FPIR) — 264; 339; 197; 359 microunits/ml
Healthy
Primary: Mean in Cerebral Metabolic Rate of Acetoacetate Before or After 4 Days of Ketogenic Diet — 0.672; 4.83 µmol/100g/min
Hyperoxaluria
Primary: Mean Percent Conversion of Hydroxyproline (Hyp) to Urinary Oxalate (UOx) — 12.8; 32.9; 14.8 percent converted
Diabetic Ketoacidosis
Primary: Patient Recruitment Rate (Feasibility Outcome) — 66 Participants